Moderna, Inc. (NASDAQ:MRNA – Get Free Report) has earned a consensus recommendation of “Reduce” from the nineteen ratings firms that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $35.7333.
Several equities research analysts have commented on MRNA shares. TD Cowen restated a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Piper Sandler upped their price target on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. Royal Bank Of Canada upped their price target on Moderna from $35.00 to $38.00 and gave the stock a “sector perform” rating in a research note on Monday, May 4th. Morgan Stanley set a $33.00 price target on Moderna in a research note on Friday, May 1st. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $45.00 price target on shares of Moderna in a research note on Tuesday, February 17th.
View Our Latest Report on Moderna
Moderna Stock Performance
Moderna (NASDAQ:MRNA – Get Free Report) last released its earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The business had revenue of $389.00 million during the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The business’s revenue for the quarter was up 260.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($2.52) earnings per share. Equities research analysts anticipate that Moderna will post -6.69 earnings per share for the current year.
Insiders Place Their Bets
In other Moderna news, President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $48.40, for a total transaction of $2,581,462.40. Following the completion of the sale, the president directly owned 1,477,997 shares in the company, valued at $71,535,054.80. This represents a 3.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Abbas Hussain sold 5,682 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the completion of the sale, the director owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,281 shares of company stock worth $3,280,293 over the last three months. 10.80% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of MRNA. MUFG Securities EMEA plc purchased a new position in Moderna in the second quarter valued at about $28,000. Flagship Harbor Advisors LLC purchased a new position in Moderna in the fourth quarter valued at about $31,000. Canton Hathaway LLC purchased a new position in Moderna in the first quarter valued at about $31,000. Ameriflex Group Inc. boosted its holdings in Moderna by 3,775.0% in the third quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after purchasing an additional 1,208 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in Moderna by 39.7% in the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after purchasing an additional 341 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.
Moderna Company Profile
Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.
Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.
Featured Stories
- Five stocks we like better than Moderna
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
